No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells

Molecular and Cellular Endocrinology

Volumn 362, Issue 1-2, 2012, Pages 149-156

  Olesen, Malene ^a   Skov, Vibe ^a,b   Mechta, Mie ^a   Mumm, Birgitte Hviid ^c   Rasmussen, Lars Melholt ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Microarray; Osteoprotegerin; RANKL; TRAIL; Vascular smooth muscle cells

Indexed keywords

INSULIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECOMBINANT CYTOKINE; RECOMBINANT OSTEOCLAST DIFFERENTIATION FACTOR; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ARTICLE; BLOOD VESSEL CALCIFICATION; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

CELL PROLIFERATION; CELLS, CULTURED; GENE KNOCKDOWN TECHNIQUES; HUMANS; INSULIN; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPROTEGERIN; RANK LIGAND; RNA INTERFERENCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTOME; VASCULAR CALCIFICATION;

EID: 84865299303     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.06.004     Document Type: Article

References (49)

1. Bitto A., De Caridi G., Polito F., Calo M., Irrera N., Altavilla D., Spinelli F., Squadrito F. Evidence for markers of hypoxia and apoptosis in explanted human carotid atherosclerotic plaques. J. Vasc. Surg. 2010, 52(4):1015-1021.
2. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H.L., Xu W., Lacey D.L., Boyle W.J., Simonet W.S. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998, 12(9):1260-1268.
3. Byon C.H., Sun Y., Chen J., Yuan K., Mao X., Heath J.M., Anderson P.G., Tintut Y., Demer L.L., Wang D., Chen Y. Runx2-upregulated receptor activator of nuclear factor {kappa}B ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler. Thromb. Vasc. Biol. 2011, 31(6):1387-1396.
4. Candido R., Toffoli B., Corallini F., Bernardi S., Zella D., Voltan R., Grill V., Celeghini C., Fabris B. Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J. Vasc. Res. 2009, 47(3):252-261.
5. Chasseraud M., Liabeuf S., Mozar A., Mentaveri R., Brazier M., Massy Z.A., Kamel S. Tumor necrosis factor-related apoptosis-inducing ligand and vascular calcification. Ther. Apher. Dial. 2011, 15(2):140-146.
6. Corallini F., Gonelli A., D'Aurizio F., di Iasio M.G., Vaccarezza M. Mesenchymal stem cells-derived vascular smooth muscle cells release abundant levels of osteoprotegerin. Eur. J. Histochem. 2009, 53(1):19-24.
7. Crisafulli A., Micari A., Altavilla D., Saporito F., Sardella A., Passaniti M., Raffa S., D'Anneo G., Luca F., Mioni C., Arrigo F., Squadrito F. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin. Sci. (Lond) 2005, 109(4):389-395.
8. Dhore C.R., Cleutjens J.P., Lutgens E., Cleutjens K.B., Geusens P.P., Kitslaar P.J., Tordoir J.H., Spronk H.M., Vermeer C., Daemen M.J. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 2001, 21(12):1998-2003.
9. Di Bartolo B.A., Schoppet M., Mattar M.Z., Rachner T.D., Shanahan C.M., Kavurma M.M. Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. Cardiovasc. Res. 2011, 91(3):537-545.
10. Doumouchtsis K.K., Kostakis A.I., Doumouchtsis S.K., Tziamalis M.P., Tsigris C., Kostaki M.A., Perrea D.N. SRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients. J. Endocrinol. Invest. 2007, 30(9):762-766.
11. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., Dul E., Appelbaum E.R., Eichman C., DiPrinzio R., Dodds R.A., James I.E., Rosenberg M., Lee J.C., Young P.R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 1998, 273(23):14363-14367.
12. Erikstrup C., Pedersen L.M., Heickendorff L., Ledet T., Rasmussen L.M. Production of hyaluronan and chondroitin sulphate proteoglycans from human arterial smooth muscle-the effect of glucose, insulin, IGF-I or growth hormone. Eur. J. Endocrinol./Eur. Fed. Endocr. Soc. 2001, 145(2):193-198.
13. Ferron M., McKee M.D., Levine R.L., Ducy P., Karsenty G. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone. 2011, 50(2):568-575.
14. Gannage-Yared M.H., Yaghi C., Habre B., Khalife S., Noun R., Germanos-Haddad M., Trak-Smayra V. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur. J. Endocrinol./Eur. Fed. Endocr. Soc. 2008, 158(3):353-359.
15. Hofbauer L.C., Dunstan C.R., Spelsberg T.C., Riggs B.L., Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem. Biophys. Res. Commun. 1998, 250(3):776-781.
16. Jono S., McKee M.D., Murry C.E., Shioi A., Nishizawa Y., Mori K., Morii H., Giachelli C.M. Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res. 2000, 87(7):E10-17.
17. Jorsal A., Tarnow L., Flyvbjerg A., Parving H.H., Rossing P., Rasmussen L.M. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia 2008, 51(11):2100-2107.
18. Kavurma M.M., Schoppet M., Bobryshev Y.V., Khachigian L.M., Bennett M.R. TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor. J. Biol. Chem. 2008, 283(12):7754-7762.
19. Kim H., Kim H.J., Lee K., Kim J.M., Kim H.S., Kim J.R., Ha C.M., Choi Y.K., Lee S.J., Kim J.Y., Harris R.A., Jeong D., Lee I.K. α-Lipoic acid attenuates vascular calcification via reversal of mitochondrial function and restoration of Gas6/Axl/Akt survival pathway. J. Cell. Mol. Med. 2012, 16(2):273-286.
20. Knudsen S.T., Foss C.H., Poulsen P.L., Andersen N.H., Mogensen C.E., Rasmussen L.M. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol/Eur. Fed.Endocr. Soc. 2003, 149(1):39-42.
21. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93(2):165-176.
22. Li C., Wong W.H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci. USA 2001, 98(1):31-36.
23. Loncar G., Bozic B., Cvorovic V., Radojicic Z., Dimkovic S., Markovic N., Prodanovic N., Lepic T., Putnikovic B., Popovic-Brkic V. Relationship between RANKL and neuroendocrine activation in elderly males with heart failure. Endocrine 2010, 37(1):148-156.
24. London G.M., Guerin A.P., Marchais S.J., Metivier F., Pannier B., Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol. Dial. Transplant. 2003, 18(9):1731-1740.
25. Malyankar U.M., Scatena M., Suchland K.L., Yun T.J., Clark E.A., Giachelli C.M. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J. Biol. Chem. 2000, 275(28):20959-20962.
26. Moran C.S., McCann M., Karan M., Norman P., Ketheesan N., Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 2005, 111(23):3119-3125.
27. Mosseri M., Satler L.F., Pichard A.D., Waksman R. Impact of vessel calcification on outcomes after coronary stenting. Cardiovasc. Revasc. Med. 2005, 6(4):147-153.
28. Ndip A., Williams A., Jude E.B., Serracino-Inglott F., Richardson S., Smyth J.V., Boulton A.J., Alexander M.Y. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy. Diabetes 2011, 60(8):2187-2196.
29. Nguyen K.Q., Olesen P., Ledet T., Rasmussen L.M. Bone morphogenetic proteins regulate osteoprotegerin and its ligands in human vascular smooth muscle cells. Endocrine 2007, 32(1):52-58.
30. O'Sullivan E.P., Ashley D.T., Davenport C., Devlin N., Crowley R., Agha A., Thompson C.J., O'Gorman D., Smith D. Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes. Diabetes Metab. Res. Rev. 2010, 26(6):496-502.
31. Olesen P., Ledet T., Rasmussen L.M. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 2005, 48(3):561-568.
32. Olesen P., Nguyen K., Wogensen L., Ledet T., Rasmussen L.M. Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high-dose insulin. Am. J. Physiol. 2007, 292(2):H1058-1064.
33. Osako M.K., Nakagami H., Koibuchi N., Shimizu H., Nakagami F., Koriyama H., Shimamura M., Miyake T., Rakugi H., Morishita R. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ. Res. 2010, 107(4):466-475.
34. Ovchinnikova O., Gylfe A., Bailey L., Nordstrom A., Rudling M., Jung C., Bergstrom S., Waldenstrom A., Hansson G.K., Nordstrom P. Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice-brief report. Arterioscler. Thromb. Vasc. Biol. 2009, 29(10):1478-1480.
35. Panizo S., Cardus A., Encinas M., Parisi E., Valcheva P., Lopez-Ongil S., Coll B., Fernandez E., Valdivielso J.M. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ. Res. 2009, 104(9):1041-1048.
36. Rasmussen L.M., Tarnow L., Hansen T.K., Parving H.H., Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol/Eur. Fed. of Endocr. Soc. 2006, 154(1):75-81.
37. Reinhard H., Lajer M., Gall M.A., Tarnow L., Parving H.H., Rasmussen L.M., Rossing P. Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care 2010, 33(12):2561-2566.
38. Sakata N., Takeuchi K., Noda K., Saku K., Tachikawa Y., Tashiro T., Nagai R., Horiuchi S. Calcification of the medial layer of the internal thoracic artery in diabetic patients: relevance of glycoxidation. J. Vasc. Res. 2003, 40(6):567-574.
39. Sandberg W.J., Yndestad A., Oie E., Smith C., Ueland T., Ovchinnikova O., Robertson A.K., Muller F., Semb A.G., Scholz H., Andreassen A.K., Gullestad L., Damas J.K., Froland S.S., Hansson G.K., Halvorsen B., Aukrust P. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler. Thromb. Vasc. Biol. 2006, 26(4):857-863.
40. Schoppet M., Al-Fakhri N., Franke F.E., Katz N., Barth P.J., Maisch B., Preissner K.T., Hofbauer L.C. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis. J. Clin. Endocrinol. Metab. 2004, 89(8):4104-4112.
41. Schoppet M., Kavurma M.M., Hofbauer L.C., Shanahan C.M. Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin. Biochem. Biophys. Res. Commun. 2011, 407(1):103-107.
42. Secchiero P., Zerbinati C., Rimondi E., Corallini F., Milani D., Grill V., Forti G., Capitani S., Zauli G. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell. Mol. Life Sci. 2004, 61(15):1965-1974.
43. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89(2):309-319.
44. Steitz S.A., Speer M.Y., Curinga G., Yang H.Y., Haynes P., Aebersold R., Schinke T., Karsenty G., Giachelli C.M. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ res 2001, 89(12):1147-1154.
45. Ueland T., Yndestad A., Oie E., Florholmen G., Halvorsen B., Froland S.S., Simonsen S., Christensen G., Gullestad L., Aukrust P. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005, 111(19):2461-2468.
46. Vik A., Mathiesen E.B., Brox J., Wilsgaard T., Njolstad I., Jorgensen L., Hansen J.B. Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso study. J. Thromb. Haemost. 2011, 9(4):638-644.
47. Wang C.C., Sorribas V., Sharma G., Levi M., Draznin B. Insulin attenuates vascular smooth muscle calcification but increases vascular smooth muscle cell phosphate transport. Atherosclerosis. 2007, 195(1):e65-e75.
48. Workman, C., Jensen, L.J., Jarmer, H., Berka, R., Gautier, L., Nielser, H.B., Saxild, H.H., Nielsen, C., Brunak, S. and Knudsen, S., 2002. A new non-linear normalization method for reducing variability in DNA microarray experiments. Genome Biol., 3(9): research 0048.
49. Zhang J., Fu M., Myles D., Zhu X., Du J., Cao X., Chen Y.E. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett. 2002, 521(1-3):180-184.